Protagonist Therapeutics, Inc. (PTGX) — Financial statements
Income statement, balance sheet, and cash flow for Protagonist Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 46↓89.4% | 434↑624.1% | 60↑125.7% | 27↓2.8% | 27 | |
| Cost of Revenue | 1 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 45↓89.7% | 434↑624.1% | 60↑125.7% | 27↓2.8% | 27 | |
| Operating Expenses | ||||||
| R&D Expenses | 159↑15.3% | 138↑15.0% | 120↓4.8% | 126↑0.2% | 126 | |
| General & Administrative Expenses | 45↑3.2% | 43↑29.8% | 33↑5.5% | 32↑16.7% | 27 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 45↑3.2% | 43↑29.8% | 33↑5.5% | 32↑16.7% | 27 | |
| Other Expenses | -1 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 203↑11.7% | 182↑18.2% | 154↓2.7% | 158↑3.1% | 153 | |
| Total Costs & Expenses | 204↑12.4% | 182↑18.2% | 154↓2.7% | 158↑3.1% | 153 | |
| Operating Results | ||||||
| Operating Income | -158↓162.5% | 253↑370.0% | -94↑28.7% | -131↓4.4% | -126 | |
| Depreciation & Amortization | 1↑48.3% | 0.83↓75.1% | 3↓1.7% | 3↑21.4% | 3 | |
| EBITDA | -128↓150.5% | 254↑380.8% | -90↑29.4% | -128↓4.0% | -123 | |
| EBIT | -129↓151.1% | 253↑370.0% | -94↑28.7% | -131↓4.4% | -126 | |
| Interest & Other Income | ||||||
| Net Interest Income | 29↑9.4% | 26↑76.6% | 15↑266.9% | 4↑816.5% | 0.44 | |
| Interest Income | 29↑9.4% | 26↑76.6% | 15↑266.9% | 4↑816.5% | 0.44 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -29 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 29↑8.5% | 27↑80.8% | 15↑269.3% | 4↑1253.7% | 0.29 | |
| Income Before Tax | -129↓146.3% | 279↑453.9% | -79↑38.0% | -127↓1.5% | -126 | |
| Income Tax Expense | 0.84↓80.1% | 4 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -130↓147.3% | 275↑448.5% | -79↑38.0% | -127↓1.5% | -126 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -130↓147.3% | 275↑448.5% | -79↑38.0% | -127↓1.5% | -126 | |
| Bottom-Line Net Income | -130↓147.3% | 275↑448.5% | -79↑38.0% | -127↓1.5% | -126 | |
| EPS (Basic) | -2.05↓145.9% | 4.47↑421.6% | -1.39↑44.8% | -2.52↑4.9% | -2.65 | |
| EPS (Diluted) | -2.05↓148.5% | 4.23↑404.3% | -1.39↑44.8% | -2.52↑4.9% | -2.65 | |
| Weighted Average Shares | 64↑3.3% | 62↑8.5% | 57↑15.7% | 49↑5.9% | 46 | |
| Weighted Average Diluted Shares | 64↓2.3% | 65↑14.6% | 57↑15.7% | 49↑5.9% | 46 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.